143 related articles for article (PubMed ID: 26631886)
1. Rapid Deterioration of the Renal Function Caused by the Coexistence of Intratubular Amyloidosis and Myeloma Cast Nephropathy.
Kato H; Fujigaki Y; Asakawa S; Yamaguchi Y; Uozaki H; Komatsuda A; Nagata M; Uchida S
Intern Med; 2015; 54(23):3023-8. PubMed ID: 26631886
[TBL] [Abstract][Full Text] [Related]
2. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
3. Two kinds of rare light chain cast nephropathy caused by multiple myeloma: case reports and literature review.
Sun LJ; Dong HR; Xu XY; Wang GQ; Cheng H; Chen YP
BMC Nephrol; 2021 Jan; 22(1):42. PubMed ID: 33509125
[TBL] [Abstract][Full Text] [Related]
4. [AL Amyloidosis].
Ueda M
Brain Nerve; 2024 May; 76(5):583-587. PubMed ID: 38741500
[TBL] [Abstract][Full Text] [Related]
5. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
Del Giudice ML; Galimberti S; Buda G
Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
[TBL] [Abstract][Full Text] [Related]
6. Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light-chain (AL) amyloidosis.
Rezk T; Salota R; Gan JJ; Lachmann HJ; Fontana M; Siew K; Martinez-Naharro A; Guillotte C; Bass P; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Dockrell M; Foard D; Lane T; Wechalekar AD; Hawkins PN; Walsh SB; Gillmore JD
Br J Haematol; 2021 Sep; 194(6):1016-1023. PubMed ID: 34374069
[TBL] [Abstract][Full Text] [Related]
7. Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group.
Maurer MS; Dunnmon P; Fontana M; Quarta CC; Prasad K; Witteles RM; Rapezzi C; Signorovitch J; Lousada I; Merlini G
Circ Heart Fail; 2022 Jun; 15(6):e009038. PubMed ID: 35331001
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma complicated with light chain cast nephropathy with focal amyloidosis: A case report.
He Y; Hua Z; Tan H; Zhao C; Liu Q; Jia J; Gao Y
Nephrology (Carlton); 2024 May; ():. PubMed ID: 38741555
[TBL] [Abstract][Full Text] [Related]
9. Unusual Case of Nephrotic Syndrome From Light Chain Amyloidosis in a 37-Year-Old Patient.
Salameh OK; Darok MC; Kane JA; Abendroth C; Trivedi N
Cureus; 2021 Sep; 13(9):e18120. PubMed ID: 34692330
[TBL] [Abstract][Full Text] [Related]
10. Intraoral hemorrhagic bullae as the first sign of immunoglobulin light chain amyloidosis.
Dominguez-Lopez RM; Naharro-Rodriguez J
CMAJ; 2024 May; 196(20):E705. PubMed ID: 38802132
[No Abstract] [Full Text] [Related]
11. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.
Monis GF; Schultz C; Ren R; Eberhard J; Costello C; Connors L; Skinner M; Trinkaus-Randall V
Am J Pathol; 2006 Dec; 169(6):1939-52. PubMed ID: 17148659
[TBL] [Abstract][Full Text] [Related]
12. How I Treat Light Chain Cast Nephropathy.
Pratt G; Pinney JH; Cockwell P
Clin J Am Soc Nephrol; 2024 May; 19(5):650-652. PubMed ID: 38109091
[No Abstract] [Full Text] [Related]
13. Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
Ravichandran S; Law S; Mahmood S; Wisniowski B; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Leukemia; 2022 Apr; 36(4):1180-1184. PubMed ID: 34987193
[No Abstract] [Full Text] [Related]
14. Relapsed systemic light chain amyloidosis - in search of a higher bar.
Baljevic M; Sengsayadeth S
Bone Marrow Transplant; 2024 Apr; 59(4):441-443. PubMed ID: 38263391
[No Abstract] [Full Text] [Related]
15. AL amyloidosis response: a move in the "light" direction.
Dispenzieri A
Blood; 2024 Mar; 143(13):1204-1206. PubMed ID: 38546635
[No Abstract] [Full Text] [Related]
16. The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney Failure.
Klank D; Löffler C; Friedrich J; Hoffmann M; Paschka P; Bergner R
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790994
[TBL] [Abstract][Full Text] [Related]
17. The Case | An active injection drug user with a skin rash and kidney failure.
Aron AW; Luciano RL
Kidney Int; 2024 Jun; 105(6):1327-1328. PubMed ID: 38777409
[No Abstract] [Full Text] [Related]
18. Non-myeloma light chain cast nephropathy: a multicenter retrospective study on clinicopathological characteristics.
Martins AC; Gibier JB; Ronsin C; Kandel-Aznar C; Moreau A; Chapal M; Francisco D; Sakhi H; Oniszczuk J; Gueguen L; Grunenwald A; Devaux M; Karras A; Royal V; Rabant M; Gnemmi V; Olagne J; Van Huyen JD; Isnard P
Haematologica; 2024 Mar; ():. PubMed ID: 38546694
[TBL] [Abstract][Full Text] [Related]
19. Nonlupus Full House Nephropathy: A Systematic Review.
Uzzo M; Kronbichler A; Alberici F; Bajema I
Clin J Am Soc Nephrol; 2024 Jun; 19(6):743-754. PubMed ID: 38527995
[No Abstract] [Full Text] [Related]
20. A Case of Immunoglobulin Light Chain Hepatic Amyloidosis with Abdominal Hematoma.
Wang H; Liu X; Xie Y; Qin X; Ma J; Qin M
Dig Dis Sci; 2024 Mar; ():. PubMed ID: 38555330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
